TRIMTECH Therapeutics
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
$47MSeed+
Role not disclosedActivity from announced rounds
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
Develops ultrasound-mediated nonviral genetic medicines
Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases